Kronos Bio Statistics
Share Statistics
Kronos Bio has 60.34M shares outstanding. The number of shares has increased by 3.39% in one year.
| Shares Outstanding | 60.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.33% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 38.65M |
| Failed to Deliver (FTD) Shares | 692 |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 527.68K, so 0.87% of the outstanding shares have been sold short.
| Short Interest | 527.68K |
| Short % of Shares Out | 0.87% |
| Short % of Float | 1.37% |
| Short Ratio (days to cover) | 8.81 |
Valuation Ratios
The PE ratio is -0.64 and the forward PE ratio is -0.67.
| PE Ratio | -0.64 |
| Forward PE | -0.67 |
| PS Ratio | 11.48 |
| Forward PS | 17 |
| PB Ratio | 0.45 |
| P/FCF Ratio | -0.91 |
| PEG Ratio | n/a |
Enterprise Valuation
Kronos Bio Inc. has an Enterprise Value (EV) of 36.13M.
| EV / Earnings | -0.32 |
| EV / Sales | 5.75 |
| EV / EBITDA | -0.3 |
| EV / EBIT | -0.3 |
| EV / FCF | -0.46 |
Financial Position
The company has a current ratio of 7.24, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.24 |
| Quick Ratio | 7.24 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.79 |
| Cash Flow / Debt | -27.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.71% and return on capital (ROIC) is -65.03%.
| Return on Equity (ROE) | -0.71% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -65.03% |
| Revenue Per Employee | 108.41K |
| Profits Per Employee | -1.94M |
| Employee Count | 58 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -34.9% in the last 52 weeks. The beta is 1.86, so Kronos Bio 's price volatility has been higher than the market average.
| Beta | 1.86 |
| 52-Week Price Change | -34.9% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 55.33 |
| Average Volume (20 Days) | 183.85K |
Income Statement
In the last 12 months, Kronos Bio had revenue of $6.29M and earned -$112.67M in profits. Earnings per share was $-1.95.
| Revenue | 6.29M |
| Gross Profit | 6.29M |
| Operating Income | -121.83M |
| Net Income | -112.67M |
| EBITDA | -121.83M |
| EBIT | -121.83M |
| Earnings Per Share (EPS) | -1.95 |
Balance Sheet
The company has $64.33M in cash and $28.27M in debt, giving a net cash position of $36.05M.
| Cash & Cash Equivalents | 64.33M |
| Total Debt | 28.27M |
| Net Cash | 36.05M |
| Retained Earnings | -508.86M |
| Total Assets | 150.02M |
| Working Capital | 112.54M |
Cash Flow
In the last 12 months, operating cash flow was -$78.58M and capital expenditures -$679.00K, giving a free cash flow of -$79.26M.
| Operating Cash Flow | -78.58M |
| Capital Expenditures | -679.00K |
| Free Cash Flow | -79.26M |
| FCF Per Share | -1.37 |
Margins
Gross margin is 100%, with operating and profit margins of -1.94K% and -1.79K%.
| Gross Margin | 100% |
| Operating Margin | -1.94K% |
| Pretax Margin | -1.79K% |
| Profit Margin | -1.79K% |
| EBITDA Margin | -1.94K% |
| EBIT Margin | -1.94K% |
| FCF Margin | -1.26K% |
Dividends & Yields
KRON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -201.03% |
| FCF Yield | -134.74% |
Analyst Forecast
The average price target for KRON is $1.62, which is 67% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.62 |
| Price Target Difference | 67% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -5.09 |
| Piotroski F-Score | 4 |